Access to effective and affordable medicines is necessary for public health, social equity, and economic development, but the biopharmaceutical sector is not meeting that need, according to a report released today by the National Academies of Sciences, Engineering, and Medicine. “Our report seeks to address the market failures that currently permeate the biopharmaceutical sector, such as lack of competition due to distortions in the application of the patent protection process, the imbalance between the negotiating power of suppliers and purchasers, and the convoluted structure of the supply chain,” the authors note. The report offers eight recommendations with 27 actions to improve the affordability of prescription drugs without discouraging the development of new and more effective drugs for the future. Among other measures, the report recommends improving methods for assessing the value that drugs provide and ensuring that incentives to develop drugs for rare diseases are not extended to widely sold drugs; taking actions to continually foster greater access to off-patent generic drugs; and discouraging direct-to-consumer advertisements for prescription drugs. 

Related News Articles

Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower…
Headline
The Government Accountability Office yesterday named two new members to the Medicaid and CHIP Payment and Access Commission.
Headline
Despite some progress in transparency related to the process for Section 1115 Medicaid waivers, the Centers for Medicare…
Chairperson's File
During Mental Health Month, let’s all remember that caring for the whole person improves health and saves lives.
Headline
he House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug…
Headline
The Centers for Medicare…